君实生物今日盘中股价大涨5.39%,引发了市场广泛关注。导致股价上涨的主要原因是其核心产品特瑞普利单抗新增4项适应症成功获批纳入国家最新的医保目录。
特瑞普利单抗是君实生物自主研发的抗PD-1单抗产品,适用于治疗黑色素瘤、非小细胞肺癌等多种肿瘤。随着4项新适应症即将于2025年1月纳入医保,特瑞普利单抗已覆盖了其所有10个国内获批适应症,成为医保目录中唯一用于上述四大肿瘤治疗的抗PD-1单抗。
医保目录的扩大将大幅提升特瑞普利单抗的可及性和销量。加之产品已在65国家和地区上市,君实生物在全球化布局方面处于领先地位。业内分析认为,特瑞普利单抗的医保纳入以及商业化前景等利好因素,支撑了公司整体盈利能力和长期发展空间,从而推高了股价。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.